Review Of Investigational New Drug Applications (Bio-Inds) By The: Fill & Download for Free

I found this on Information Clearing HouseHave a look at this timeline published by an American pharmaceutical research company. Moderna’s Work on a Potential Vaccine Against COVID-19_________________________________________________________________“MODERNA is proud to be among the many groups working to respond to this continuing global health emergency. This page summarizes key milestones in our work to advance our vaccine candidate (mRNA-1273) and responds to frequently asked questions.Timeline Of Our Response Through March 16, 2020On January 11, 2020, the Chinese authorities shared the genetic sequence of the novel coronavirus.On January 13, 2020, the U.S. National Institutes of Health (NIH) and Moderna’s infectious disease research team finalized the sequence for mRNA-1273, the Company’s vaccine against the novel coronavirus. At that time, the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, disclosed their intent to run a Phase 1 study using the mRNA-1273 vaccine in response to the coronavirus threat and Moderna mobilized toward clinical manufacture. Manufacture of this batch was funded by the Coalition for Epidemic Preparedness Innovations (CEPI).HEY THAT’S ONLY 2 DAYS AFTER THEY GOT THE GENETIC SEQUENCE. WHAT A MIRACLE, A VACCINE IN 2 DAYS.On February 7, 2020, the first clinical batch, including fill and finishing of vials, was completed, a total of 25 days from sequence selection to vaccine manufacture. The batch then proceeded to analytical testing for release.On February 24, 2020, the clinical batch was shipped from Moderna to the NIH for use in their Phase 1 clinical study.On March 4, 2020, the U.S. Food and Drug Administration (FDA) completed its review of the Investigational New Drug (IND) application filed by the NIH for mRNA-1273 and allowed to the study to proceed to begin clinical trials.On March 16, 2020, the NIH announced that the first participant in its Phase 1 study for mRNA-1273 was dosed, a total of 63 days from sequence selection to first human dosing. Moderna’s Work on a Potential Vaccine Against COVID-19_________________________________________Moderna does work for the Defense Advanced Research Projects Agency (DARPA) to research and develop its mRNA drug technology to fight biological weapons.If I was suspicious I would be thinking about how no biological warfare agent is going to be useful unless you have a vaccine for your own troops and ruling class.THIS SMELLS, NO IT STINKS TO HIGH HEAVEN.”____________________________________________________________________________I agree. It seems that this particular virus was already well known in certain labs and government agencies in America. Thank you Pennotasword.Update: This post was taken off Information Clearing House shortly after I posted it here. I’m sure it wasn’t the blog’s creator Tom.